- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Cutis laxa.
Displaying page 1 of 1.
EudraCT Number: 2016-004110-10 | Sponsor Protocol Number: 2ABC | Start Date*: 2017-12-21 | ||||||||||||||||
Sponsor Name:Medical University of Warsaw | ||||||||||||||||||
Full Title: Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The t... | ||||||||||||||||||
Medical condition: Scar or cutis laxa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024215-14 | Sponsor Protocol Number: C25001 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma | |||||||||||||
Medical condition: CD30-Positive Cutaneous T-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003879-12 | Sponsor Protocol Number: MK-0683 042-00 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma | |||||||||||||
Medical condition: Cutaneous T-cell lymphoma (CTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Completed) DK (Completed) FI (Completed) SI (Completed) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000433-30 | Sponsor Protocol Number: UCL/17/0053 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma | |||||||||||||
Medical condition: Cutaneous T cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001076-18 | Sponsor Protocol Number: 26481585LYM2001 | Start Date*: 2011-09-20 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma | |||||||||||||
Medical condition: Stage Ib-IVa Cutaneous T-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000914-12 | Sponsor Protocol Number: GASOLINE | Start Date*: 2020-06-12 | ||||||||||||||||||||||||||
Sponsor Name:University of Cologne | ||||||||||||||||||||||||||||
Full Title: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor) • Prostate carcino... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020363-21 | Sponsor Protocol Number: SGN35-010 | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma | |||||||||||||
Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005039-34 | Sponsor Protocol Number: ASTX660-01 | Start Date*: 2018-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas | |||||||||||||||||||||||||||||||||
Medical condition: Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinoma; cohort 2:Relapsed or refractory diffuse large B-cell ly... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Temporarily Halted) FR (Completed) HU (Completed) ES (Ongoing) BE (Completed) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
